Elevance Health (NYSE:ELV) Releases FY 2026 Earnings Guidance

Elevance Health (NYSE:ELV) updated its FY 2026 earnings guidance on Friday morning. The company provided earnings per share guidance of 27.000- for the period, compared to the consensus earnings per share estimate of 26.890. The company issued revenue guidance of -.

Elevance Health Trading Down 0.3%

Shares of NYSE:ELV traded down $0.96 during trading hours on Friday, hitting $375.44. 976,869 shares of the company’s stock traded hands, compared to its average volume of 1,786,755. The firm has a market capitalization of $81.42 billion, a P/E ratio of 16.69, a price-to-earnings-growth ratio of 2.16 and a beta of 0.67. The business has a fifty day moving average price of $397.38 and a 200-day moving average price of $356.68. Elevance Health has a 1 year low of $273.71 and a 1 year high of $436.24. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.52 and a quick ratio of 1.52.

Elevance Health (NYSE:ELV) last issued its quarterly earnings results on Wednesday, July 15th. The company reported $7.45 earnings per share for the quarter, topping the consensus estimate of $6.21 by $1.24. Elevance Health had a return on equity of 14.64% and a net margin of 2.47%.The firm had revenue of $49.83 billion for the quarter, compared to the consensus estimate of $48.88 billion. During the same period in the prior year, the business posted $8.84 earnings per share. The company’s revenue for the quarter was up .8% on a year-over-year basis. Equities analysts expect that Elevance Health will post 27.04 earnings per share for the current year.

Elevance Health Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 25th. Stockholders of record on Thursday, September 10th will be given a dividend of $1.72 per share. This represents a $6.88 annualized dividend and a dividend yield of 1.8%. The ex-dividend date is Thursday, September 10th. Elevance Health’s dividend payout ratio (DPR) is 30.58%.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the stock. Leerink Partners boosted their target price on shares of Elevance Health from $364.00 to $395.00 and gave the company a “market perform” rating in a research note on Friday, July 17th. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $395.00 price target on shares of Elevance Health in a research note on Thursday, July 16th. Wells Fargo & Company decreased their price objective on shares of Elevance Health from $492.00 to $473.00 and set an “overweight” rating for the company in a report on Thursday, July 16th. Truist Financial boosted their price objective on shares of Elevance Health from $450.00 to $475.00 and gave the company a “buy” rating in a research report on Tuesday, July 14th. Finally, Jefferies Financial Group dropped their target price on shares of Elevance Health from $395.00 to $391.00 and set a “buy” rating on the stock in a research note on Monday, April 20th. Fifteen analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company. Based on data from MarketBeat.com, Elevance Health currently has an average rating of “Moderate Buy” and an average target price of $440.90.

Insider Activity at Elevance Health

In related news, Director Robert L. Dixon, Jr. sold 151 shares of Elevance Health stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $401.77, for a total value of $60,667.27. Following the completion of the sale, the director directly owned 10,734 shares in the company, valued at $4,312,599.18. The trade was a 1.39% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Corporate insiders own 0.34% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the business. Compound Planning Inc. boosted its stake in shares of Elevance Health by 19.9% during the fourth quarter. Compound Planning Inc. now owns 1,060 shares of the company’s stock valued at $372,000 after purchasing an additional 176 shares in the last quarter. Claris Financial LLC bought a new position in Elevance Health in the fourth quarter worth approximately $358,000. Axxcess Wealth Management LLC lifted its holdings in Elevance Health by 27.8% during the fourth quarter. Axxcess Wealth Management LLC now owns 1,767 shares of the company’s stock worth $619,000 after buying an additional 384 shares during the period. Corient Private Wealth LLC lifted its holdings in Elevance Health by 45.7% during the fourth quarter. Corient Private Wealth LLC now owns 87,355 shares of the company’s stock worth $30,622,000 after buying an additional 27,409 shares during the period. Finally, Alberta Investment Management Corp boosted its position in Elevance Health by 63.8% during the 4th quarter. Alberta Investment Management Corp now owns 17,200 shares of the company’s stock valued at $6,029,000 after acquiring an additional 6,700 shares in the last quarter. Hedge funds and other institutional investors own 89.24% of the company’s stock.

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.